Emerging Targets and Therapeutics in the Treatment of Psychostimulant Abuse

Emerging Targets and Therapeutics in the Treatment of Psychostimulant Abuse

1st Edition - January 29, 2014

Write a review

  • Editor: Linda P. Dwoskin
  • eBook ISBN: 9780124201774

Purchase options

Purchase options
DRM-free (PDF, EPub, Mobi)
Sales tax will be calculated at check-out

Institutional Subscription

Free Global Shipping
No minimum order

Description

This new volume of Advances in Pharmacology presents the emerging targets and therapeutics in the treatment of psychostimulant abuse. With a variety of chapters and the best authors in the field, the volume is an essential resource for pharmacologists, immunologists and biochemists alike.

Key Features

  • Contributions from the best authors in the field
  • An essential resource for pharmacologists, immunologists, and biochemists

Readership

Pharmacologists, immunologists, and biochemists

Table of Contents

  • Preface
    Contributors
    Chapter One: Glial Modulators as Potential Treatments of Psychostimulant Abuse
    Abstract

    1 Introduction

    2 Molecular Biology and Physiology of the Glia

    3 In Vivo Evidence that Modulating Glia and Neuroinflammation Provide Pharmacotherapeutic Possibilities for Psychostimulant Abuse

    4 Ongoing or Planned Clinical Studies Examining Glial Modulators in the Treatment of Psychostimulant Abuse

    5 Conclusion

    Conflict of Interest

    Chapter Two: The Vesicular Monoamine Transporter-2
    Abstract

    1 Methamphetamine Addiction

    2 Methamphetamine: Mechanism of Action

    3 Identification and Classification of Vesicular Monoamine Transporters

    4 VMAT2 Function

    5 VMAT2 Binding Sites

    6 Aberrant VMAT2 Expression and Function

    7 Conclusion

    Conflict of Interest

    Acknowledgments

    Chapter Three: Customizing Monoclonal Antibodies for the Treatment of Methamphetamine Abuse
    Abstract

    1 Introduction

    2 METH Mechanisms of Action, Toxicity, and Current Therapies

    3 Therapeutic Monoclonal Antibodies to Counteract METH Effects

    4 Predicting Therapeutic Effectiveness

    5 METH Metabolism and Pharmacokinetics: Choosing the Appropriate Animal Testing Model

    6 The Role of Affinity, Binding Capacity, and In Vivo Modifications in mAb Function

    7 Hapten Design for Improved Target Specificity and mAb Functionality

    8 Relationship Between Hapten Structure and mAb Function: Application to Other Antibody Forms

    9 Antibody Form and Duration of Action

    10 Conclusion

    Conflict of Interest

    Acknowledgments

    Chapter Four: Monoamine Transporter Inhibitors and Substrates as Treatments for Stimulant Abuse
    Abstract

    1 Introduction

    2 Operant Behavior in Medication Development

    3 Monoamine Transporters as Molecular Targets for Medication Development

    4 Evaluation of Monoamine Transporter Inhibitors and Substrates on Abuse-Related Effects of Psychostimulants

    5 Conclusion

    Conflict of Interest

    Acknowledgments

    Chapter Five: Bupropion and Bupropion Analogs as Treatments for CNS Disorders
    Abstract

    1 Introduction

    2 Metabolism of Bupropion

    3 Mechanism of Bupropion Therapeutic Properties

    4 Animal Behavioral Studies of Bupropion

    5 Clinical Studies with Bupropion

    6 Bupropion nAChR Binding Site

    7 Bupropion and Hydroxybupropion Analog Clinical Development

    8 Conclusion

    Conflict of Interest

    Acknowledgments

    Chapter Six: The Role of Guanfacine as a Therapeutic Agent to Address Stress-Related Pathophysiology in Cocaine-Dependent Individuals
    Abstract

    1 Introduction

    2 Guanfacine as a Medication for Substance Abuse Compared with Other Alpha-2 Adrenergic Agonists

    3 Other Potential Anxiolytics and Cognitive Enhancers

    4 Long-Term Maintenance of Guanfacine

    5 Conclusion

    Conflict of Interest

    Chapter Seven: Beyond Small-Molecule SAR
    Abstract

    1 Introduction

    2 D3-Selective Drug Design Using Small-Molecule SAR

    3 Clinical Studies Targeting the D3 Receptor in the Treatment of Addiction

    4 The Structural Basis of D3 over D2 Receptor Selectivity and the Future of Rational Drug Design for D3 Receptor-Selective Ligands

    5 Conclusion

    Conflict of Interest

    Acknowledgments

    Chapter Eight: Dopamine D4 Receptors in Psychostimulant Addiction
    Abstract

    1 Introduction

    2 DRD4 and Psychostimulant Addiction

    3 Conclusion

    Conflict of Interest

    Acknowledgments

    Chapter Nine: Sigma (σ) Receptors as Potential Therapeutic Targets to Mitigate Psychostimulant Effects
    Abstract

    1 Introduction

    2 Background on σ Receptors

    3 Cocaine and σ Receptors

    4 Methamphetamine and σ Receptors

    5 Clinical Implications

    6 Conclusion

    Conflict of Interest

    Acknowledgments

    Chapter Ten: Mixed Kappa/Mu Partial Opioid Agonists as Potential Treatments for Cocaine Dependence
    Abstract

    1 Introduction

    2 Opioids Used to Treat Drug and Alcohol Dependence: Preclinical and Clinical Evidence

    3 Mechanistic and In Vitro Characterization of Mixed μ/κ Agonists

    4 Conclusion

    Conflict of Interest

    Acknowledgments

    Chapter Eleven: The Combination of Metyrapone and Oxazepam for the Treatment of Cocaine and Other Drug Addictions
    Abstract

    1 Introduction

    2 Stress and Addiction

    3 Cocaine and Benzodiazepines

    4 Stress and Cocaine Reinforcement

    5 Stress and Relapse

    6 Rationale for Testing Drug Combinations

    7 Our Hypothesis Changes

    8 Medial Prefrontal Cortex and Cocaine

    9 Neurosteroids and the Combination of Metyrapone and Oxazepam

    10 Conclusion

    Conflict of Interest

    Chapter Twelve: Salvinorin A Analogs and Other Kappa-Opioid Receptor Compounds as Treatments for Cocaine Abuse
    Abstract

    1 Introduction

    2 Kappa-Opioid Receptors and the Endogenous Opioid System

    3 Kappa-Opioid Regulation of Dopamine Systems

    4 Effects of Drugs of Abuse on the Kappa-Opioid System

    5 Effects of Kappa-Opioid Receptor Agonists on Drug Addiction

    6 Animal Studies with Sal A

    7 Effects of Sal A on Depression

    8 Antidepressive Effects of Sal A

    9 Prodepressive Effects of Sal A

    10 Signaling Pathways Regulated by Sal A

    11 Pharmacokinetics of Sal A

    12 Sal A Analogs

    13 Conclusion

    Conflict of Interest

    Chapter Thirteen: Nicotinic Receptor Antagonists as Treatments for Nicotine Abuse
    Abstract

    1 Introduction

    2 Current Smoking Cessation Therapies that Target nAChRs

    3 Emerging Potential Therapeutics for Treatment of Tobacco Dependence

    4 Small-Molecule Surrogates of α-CtxMII as Smoking Cessation Agents

    5 Monoquaternary Ammonium Salts Derived from N-Methylnicotinium Ion as Nicotinic Receptor Antagonists

    6 Conclusion

    Conflict of Interest

    Acknowledgments

    Chapter Fourteen: New Directions in Nicotine Vaccine Design and Use
    Abstract

    1 Introduction

    2 Status of First-Generation Nicotine Vaccines

    3 Limitations of First-Generation Nicotine Vaccines

    4 Limitations of Vaccination as a General Strategy for Treating Nicotine Addiction

    5 Design of Nicotine Vaccines

    6 Strategies for Improving Vaccine Efficacy

    7 Alternatives to Vaccination

    8 Translational Considerations

    9 Conclusion

    Conflict of Interest

    Acknowledgments

    Chapter Fifteen: Bath Salts, Mephedrone, and Methylenedioxypyrovalerone as Emerging Illicit Drugs That Will Need Targeted Therapeutic Intervention
    Abstract

    1 Introduction

    2 PIA Analogs: Nomenclature and Pharmacological Assays

    3 Cathinone Analogs: Historical Perspectives

    4 Amphetamine (i.e., Phenylisopropylamine) Analogs

    5 Synthetic Cathinones: Specific Agents

    6 Synthetic Cathinones: Mechanisms of Action and Behavioral Studies

    7 Synthetic Cathinones: Human Studies

    8 Conclusion

    Conflict of Interest

    Acknowledgments

    Index

Product details

  • No. of pages: 656
  • Language: English
  • Copyright: © Academic Press 2014
  • Published: January 29, 2014
  • Imprint: Academic Press
  • eBook ISBN: 9780124201774

About the Editor

Linda P. Dwoskin

Affiliations and Expertise

Pharmaceutical Education, College of Pharmacy, University of Kentucky, Lexington, KY, USA

Ratings and Reviews

Write a review

There are currently no reviews for "Emerging Targets and Therapeutics in the Treatment of Psychostimulant Abuse"